For traders, this data de-risks MICVO's monotherapy profile and sets a clear catalyst path: combo data (Q4 2026), End of Phase 2 meeting (Q1 2027), updated overall survival (1H 2027), and Phase 3 initiation (mid-2027). Monitor for any safety signals as the trial expands (peripheral neuropathy Gr3 in 17.1% of patients).
Price Chart
Executive Summary
Pyxis Oncology announced positive updated Phase 1 monotherapy data for micvotabart pelidotin (MICVO) in second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma (2L+ R/M HNSCC). The data show a 36% confirmed objective response rate, 94% disease control rate, median progression-free survival of 6.2 months, and a 12-month overall survival probability of 79% — substantially exceeding historical control benchmarks. Safety was manageable with dose capping, supporting advancement into a pivotal Phase 3 trial (Headliner) planned for mid-2027.
Key Facts
- 36% confirmed objective response rate (cORR) and 94% disease control rate (DCR) in 2L+ R/M HNSCC (N=33 efficacy evaluable)
- Median progression-free survival (mPFS) of 6.2 months; 12-month overall survival probability of 79% (median OS not yet reached)
- Clinical activity observed across HPV status and prior-treatment subgroups, including prior EGFRi-exposed patients
- No new safety signals; dose capping reduced frequency and severity of adverse events, especially peripheral neuropathy
- Phase 3 Headliner trial planned for mid-2027; End of Phase 2 meeting with FDA expected Q1 2027
- Updated data from MICVO + KEYTRUDA (pembrolizumab) combination in 1L R/M HNSCC expected Q4 2026
Financial Impact
No financial data in filing; positive clinical data supports potential for a multi-billion-dollar addressable market (>$4B US TAM in 2L+ HNSCC per company estimates) but revenue still zero as company is pre-commercial
Risk Factors
- Early stage: Phase 1 data, small sample size (N=33 efficacy evaluable), and cross-trial comparisons are not head-to-head
- Safety: Grade 3 peripheral neuropathy in 17.1% and 14% discontinuation rate; need to monitor in larger Phase 3
- Competitive landscape: novel EGFRi therapies (e.g., petosemtamab) may shift 1L treatment and affect 2L+ trial enrollment
- Regulatory risk: Phase 3 design requires alignment with FDA on dose selection (Project Optimus) and co-primary endpoints (ORR and OS)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-385901 |
| Document: pyxs-ex99_1.htm | 0001193125-26-385901 |
| Document: pyxs-ex99_2.htm | 0001193125-26-385901 |
| Document: 0001193125-26-385901-index-headers.html | 0001193125-26-385901 |
| Document: 0001193125-26-385901-index.html | 0001193125-26-385901 |
| Document: 0001193125-26-385901.txt | 0001193125-26-385901 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | 8-K | $3.38 $3.34 | ▼ −1.18% | ▼ −0.09% | $2.19 (−35.21%) |
Sep 8, 2026 24d ago | 8-K | $3.89 $3.33 | ▼ −14.40% | ▼ −13.28% | $2.19 (−43.70%) |
Aug 28, 2026 5w ago | EFFECT | $3.23 $3.89 | ▼ −20.43% | ▼ −20.32% | $2.19 (+32.20%) |
Aug 13, 2026 7w ago | 8-K | $3.01 $3.12 | ▲ +3.65% | ▲ +5.62% | $2.19 (−27.24%) |
Jul 2, 2026 13w ago | 8-K | $2.63 $2.64 | ▲ +0.38% | ▼ −0.55% | $2.19 (−16.73%) |
Jun 30, 2026 13w ago | 144 | $2.85 $3.07 | ▲ +7.72% | ▲ +7.46% | $2.19 (−23.16%) |
Jun 30, 2026 13w ago | Press Release | $3.01 $2.46 | ▼ −18.27% | ▼ −18.88% | $2.19 (−27.24%) |
May 14, 2026 20w ago | 8-K | $2.21 $1.94 | ▼ −12.22% | ▼ −11.50% | $2.19 (−0.90%) |
May 14, 2026 20w ago | Press Release | $2.21 $1.94 | ▼ −12.22% | ▼ −11.50% | $2.19 (−0.90%) |
Apr 30, 2026 22w ago | DEFA14A | $1.70 $2.26 | ▲ +32.94% | ▲ +31.21% | $2.19 (+28.82%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access